Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Gene Therapy for Parkinson's disease
jRCT2033250070Phase 2Suspended
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AAV-AADC/GCH/TH in Parkinson's disease (PD), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary endpoint: Safety and efficacy of AAV-AADC/GCH/TH. Started May 2025; status: suspended.
02
Drugs
AAV-AADC/GCH/TH
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2033250070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250070.